New findings suggest that the HSD3B1 genotype can be used to risk stratify white men with low-volume metastatic prostate cancer.
Rates of regional- and distant-stage prostate cancer increasing in the US among men older than 50 years.
The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
TMPRSS2, a serine protease expressed in prostate and lung tissue that is necessary for SARS-CoV-2 viral infectivity of host cells, is activated by the androgen receptor.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.
Post hoc analysis of the PROMIS cohort shows that tumors undetected by mpMRI are smaller and of lower grade than those that are detected.
Tissue biopsies to diagnose prostate cancer are invasive and they often miss cancer cells, which limits their utility for diagnosis.
Men with metastatic castration-resistant prostate cancer and symptomatic bone metastases had longer survival times when they received radium-223 as first-line therapy compared with those who received the drug as third-line therapy.
Atezolizumab plus enzalutamide failed to improve OS compared with enzalutamide alone among patients with mCRPC in the IMbassador250 trial.